Company profile
ADDEX THERAPEUTICS LTD.
NASDAQ:ADXNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DIPRAGLURANT | phase2_3 | — | 4 | completed, terminated |
| RASEGLURANT | phase2 | — | 3 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00820105 | phase2 | terminated | 2008-12-01 | 2010-01-01 | Addex Pharma S.A. | ADX10059 Migraine Prevention Study |
| NCT00820079 | phase2 | completed | 2008-12-01 | 2009-10-01 | Addex Pharma S.A. | ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) |
| NCT00810485 | phase2 | completed | 2008-12-01 | 2009-12-01 | Addex Pharma S.A. | ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) |
| NCT01336088 | phase2 | completed | 2011-04-01 | 2012-02-01 | Addex Pharma S.A. | ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease |
| NCT04857359 | phase2_3 | terminated | 2021-08-06 | 2022-06-17 | Addex Pharma S.A. | Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
FDA applications (0)
No records yet.